This is a contrast between Global Cord Blood Corporation (NYSE:CO) and Arbutus Biopharma Corporation (NASDAQ:ABUS) based on their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood Corporation	N/A	0.00	N/A	0.28	26.39
Arbutus Biopharma Corporation	5.95M	33.89	67.15M	-1.81	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Global Cord Blood Corporation and Arbutus Biopharma Corporation.

Profitability

Table 2 has Global Cord Blood Corporation and Arbutus Biopharma Corporation’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Global Cord Blood Corporation	0.00%	7.2%	3.8%
Arbutus Biopharma Corporation	-1,128.57%	-72.9%	-32.3%

Risk & Volatility

Global Cord Blood Corporation’s volatility measures that it’s 59.00% less volatile than S&P 500 due to its 0.41 beta. In other hand, Arbutus Biopharma Corporation has beta of 1.81 which is 81.00% more volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Global Cord Blood Corporation are 9.7 and 9.6. Competitively, Arbutus Biopharma Corporation has 11.4 and 11.4 for Current and Quick Ratio. Arbutus Biopharma Corporation’s better ability to pay short and long-term obligations than Global Cord Blood Corporation.

Dividends

Global Cord Blood Corporation pays out its dividends annually at $0.08 per share and 1.1% dividend yield. No dividend is paid out for Arbutus Biopharma Corporation.

Institutional & Insider Ownership

The shares of both Global Cord Blood Corporation and Arbutus Biopharma Corporation are owned by institutional investors at 17.4% and 43.8% respectively. Insiders owned roughly 49.6% of Global Cord Blood Corporation’s shares. Comparatively, Arbutus Biopharma Corporation has 3.1% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Global Cord Blood Corporation	3.79%	17.68%	15.29%	6.79%	-29.82%	14.57%
Arbutus Biopharma Corporation	10.17%	20.33%	-4.1%	-50.11%	-17.01%	15.93%

For the past year Global Cord Blood Corporation’s stock price has smaller growth than Arbutus Biopharma Corporation.

Summary

Global Cord Blood Corporation beats Arbutus Biopharma Corporation on 7 of the 11 factors.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.